Adalvo announces the addition of Olaparib Film Coated Tablets to its expanding oncology portfolio.
As a leading PARP inhibitor, Olaparib has received the most FDA approvals across four tumor types, underscoring its critical role in oncological treatment. Based on the reference brand, LYNPARZA, Olaparib is indicated for the treatment of ovarian cancer, breast cancer, adenocarcinoma of the pancreas, and prostate cancer, offering versatile treatment options.
With its initial approval as the first drug in the U.S. for advanced ovarian cancer in patients with defective BRCA genes, Olaparib demonstrates significant potential for lifecycle expansion both as a monotherapy and in combination therapies.
Adalvo's strategic IP pathway ensures a Day-1 generic launch opportunity in major markets.
Adalvo anticipates Olaparib's EU sales to reach approximately $1300 million by 2028, reflecting our commitment to delivering differentiated oncology solutions to patients globally.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Partner Up Now!